Prehospital Resuscitation Intranasal Cooling Effects Seen in MRI of the Brain After Cardiac Arrest

NCT ID: NCT02179060

Last Updated: 2018-03-21

Basic Information

• Recruitment Status: TERMINATED
• Total Enrollment: 12 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2014-06-30
• Study Completion Date: 2016-04-01

Brief Summary

Therapeutic hypothermia improves the neurologically-intact survival rates in those patients resuscitated out-of-hospital from ventricular fibrillation. Cooling as early as possible might be beneficial to those victims. Diffusion Tensor Imaging and diffusion-weighted magnetic resonance imaging have recently shown to be able to identify early ischemia-related changes within the brain three days after cardiac arrest, among sudden cardiac arrest patients cooled in hospital. The physical changes seen within the brain may be able to distinguish survivors at very early phase.

This study aims to assess early ischemia-related changes of the brain seen in MRI approximately three days after cardiac arrest. The hypotheses is that MRI will differ in the groups of patients treated with early intra-arrest cooling with the RhinoChill device and in hospital hypothermia in 36 Celsius, in the group of patients treated with normal in hospital hypothermia in 36 Celsius only, in the group of patients treated with normal in hospital hypothermia in 33 Celsius only (The historical Xenon study patients). The primary endpoint is the presence and pattern of white matter and gray matter degeneration and volumetric changes of the gray matter, white matter, and cerebro-spinal fluid spaces in MRI, and secondary endpoints are total survival at 90 days, and time to reach a target temperature (≤36/33 Celsius).

Detailed Description

Medical personnel (e.g,. nurses or physicians) responding to a cardiac arrest will assess each patient for study inclusion. During resuscitation patients will receive standard ALS (advanced life support) according to European Resuscitation Council (ERC) guidelines with cooling with the RhinoChill upon determining that the patient is in cardiac arrest. The RhinoChill catheters should be placed and cooling initiated immediately after airway management (i.e. laryngeal mask or intubation). The aim is that cooling should be started within 15 minutes from the call to the dispatch centre. Specifically, cooling with chilled saline or cold packs in the field or ambulance will not be permitted. Resuscitation attempts should be continued for at least 45 minutes after the collapse in all patients having venticular fibrillation (VF) or non-perfusive venticular tachycardia (VT) as initial cardiac rhythm before deciding that further interventions are futile.

Automated external defibrillator (AEDs) with the capability to record data will be used in each resuscitation attempt, and the quality of cardio pulmonary resuscitation (CPR) is followed.

RhinoChill cooling will be continued in those subjects that achieve ROSC and remain comatose. Bolus doses of sedation and analgesia will be administered for their transport to the hospital according to local protocol. RhinoChill cooling will be continued at the hospital until the subject can be successfully transitioned to the standard institutional cooling protocol.

Clinical assessments and clinically relevant adverse events will be documented from the time the patient is enrolled to the study until the first of the following two events occur: death or MRI scan.

Patients that regain consciousness following ROSC and prior to hospital transport will be excluded. Patient's still unconscious in the emergency room are admitted to ICU and therapeutic cooling is continued for 24 to 36 hours. The MRI scan will take place within 16 hours after rewarming. After that the sedation is stopped and patient extubated if possible. The study is finished at that point and normal patient care continues.

The study continues until 10 patients with MRI scan are enrolled in Tampere University Hospital (TAUH).

Conditions

Cardiac Arrest

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Study Groups

Cooling group

The RhinoChill® cooling is started as soon as possible to the patients with Cardiac arrest, and before the return of spontaneous circulation

No interventions assigned to this group

Control group

Standard care, no cooling during pre-hospital care

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

1. Ventricular fibrillation or non-perfusive ventricular tachycardia as initial cardiac rhythm.

2. The 1st attempt at resuscitation by emergency medical personnel must appear within 15 minutes after the collapse.

3. The cause for collapse should be considered primary as cardiogenic and the return of spontaneous circulation (ROSC) should have been gained in 45 minutes after the collapse.

4. Patient should be still unconscious in the emergency room.

5. Age: 18 - 80 years

6. Obtained consent after arrival to the hospital, and before MRI scan.

Exclusion Criteria

7. Hypothermia (< 30°C core temperature)

8. Arrival of EMS after 15 minutes from collapse

9. Unconsciousness before cardiac arrest (cerebral trauma, spontaneous cerebral haemorrhages, intoxications etc.)

10. Terminal phase of a chronic disease, or known limitations in therapy and Do Not Resuscitate-order or known pre-arrest Cerebral Performance Category 3 or 4

11. Factors making participation in follow-up unlikely

12. Factors making the RhinoChill cooling contraindicated: patients with known contraindications to hypothermia (Raynaud's disease, Cryoglobulinemia, Sickle Cell disease), have specific temperature-sensitive pathologies (e.g., serum cold agglutinins, Buerger's disease), intranasal obstruction, or known skull base fracture.

13. Pregnancy

14. Coagulopathy

15. Response to verbal commands after the return of spontaneous circulation (ROSC)

16. Systolic arterial pressure < 80 mmHg or mean arterial pressure < 60 mmHg for over 30 min period after ROSC

17. Evidence of hypoxemia (arterial oxygen saturation < 85%) for > 15 minutes after ROSC

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Turku University Hospital

OTHER_GOV

Sponsor Role: collaborator

Helsinki University Central Hospital

OTHER

Sponsor Role: collaborator

BeneChill, Inc

INDUSTRY

Sponsor Role: collaborator

Tampere University Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Sanna Hoppu, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Locations

Tampere University hospital

Tampere, , Finland

Countries

Finland

Other Identifiers

R14025

Identifier Type: -

Identifier Source: org_study_id